Cargando…

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus

BACKGROUND: Tembusu virus (TMUV), a newly emerging pathogenic flavivirus, spreads rapidly between ducks, causing massive economic losses in the Chinese duck industry. Vaccination is the most effective method to prevent TMUV. Therefore, it is urgent to look for an effective vaccine strategy against T...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yuting, Jia, Renyong, Li, Juping, Wang, Mingshu, Chen, Shun, Liu, Mafeng, Zhu, Dekang, Zhao, Xinxin, Wu, Ying, Yang, Qiao, Yin, Zhongqiong, Jing, Bo, Huang, Juan, Zhang, Shaqiu, Zhang, Lin, Liu, Yunya, Yu, Yanlin, Tian, Bin, Pan, Leichang, Rehman, Mujeeb Ur, Cheng, Anchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218524/
https://www.ncbi.nlm.nih.gov/pubmed/32398028
http://dx.doi.org/10.1186/s12985-020-01334-w
_version_ 1783532815545008128
author Pan, Yuting
Jia, Renyong
Li, Juping
Wang, Mingshu
Chen, Shun
Liu, Mafeng
Zhu, Dekang
Zhao, Xinxin
Wu, Ying
Yang, Qiao
Yin, Zhongqiong
Jing, Bo
Huang, Juan
Zhang, Shaqiu
Zhang, Lin
Liu, Yunya
Yu, Yanlin
Tian, Bin
Pan, Leichang
Rehman, Mujeeb Ur
Cheng, Anchun
author_facet Pan, Yuting
Jia, Renyong
Li, Juping
Wang, Mingshu
Chen, Shun
Liu, Mafeng
Zhu, Dekang
Zhao, Xinxin
Wu, Ying
Yang, Qiao
Yin, Zhongqiong
Jing, Bo
Huang, Juan
Zhang, Shaqiu
Zhang, Lin
Liu, Yunya
Yu, Yanlin
Tian, Bin
Pan, Leichang
Rehman, Mujeeb Ur
Cheng, Anchun
author_sort Pan, Yuting
collection PubMed
description BACKGROUND: Tembusu virus (TMUV), a newly emerging pathogenic flavivirus, spreads rapidly between ducks, causing massive economic losses in the Chinese duck industry. Vaccination is the most effective method to prevent TMUV. Therefore, it is urgent to look for an effective vaccine strategy against TMUV. Heterologous prime-boost regimens priming with vaccines and boosting with recombinant adenovirus vaccines have been proven to be successful strategies for protecting against viruses in experimental animal models. METHODS: In this study, heterologous and homologous prime-boost strategies using an attenuated salmonella vaccine and a recombinant adenovirus vaccine expressing prM-E or the E gene of TMUV were evaluated to protect ducks against TMUV infection for the first time, including priming and boosting with the attenuated salmonella vaccine, priming and boosting with the recombinant adenovirus vaccine, and priming with the attenuated salmonella vaccine and boosting with the recombinant adenovirus vaccine. Humoral and cellular immune responses were detected and evaluated. We then challenged the ducks with TMUV at 12 days after boosting to assay for clinical symptoms, mortality, viral loads and histopathological lesions after these different strategies. RESULTS: Compared with the homologous prime-boost strategies, the heterologous prime-boost regimen produced higher levels of neutralizing antibodies and IgG antibodies against TMUV. Additionally, it could induce higher levels of IFN-γ than homologous prime-boost strategies in the later stage. Interestingly, the heterologous prime-boost strategy induced higher levels of IL-4 in the early stage, but the IL-4 levels gradually decreased and were even lower than those induced by the homologous prime-boost strategy in the later stage. Moreover, the heterologous prime-boost strategy could efficiently protect ducks, with low viral titres, no clinical symptoms and histopathological lesions in this experiment after challenge with TMUV, while slight clinical symptoms and histopathological lesions were observed with the homologous prime-boost strategies. CONCLUSIONS: Our results indicated that the heterologous prime-boost strategy induced higher levels of humoral and cellular immune responses and better protection against TMUV infection in ducks than the homologous prime-boost strategies, suggesting that the heterologous prime-boost strategy is an important candidate for the design of a novel vaccine strategy against TMUV.
format Online
Article
Text
id pubmed-7218524
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72185242020-05-18 Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus Pan, Yuting Jia, Renyong Li, Juping Wang, Mingshu Chen, Shun Liu, Mafeng Zhu, Dekang Zhao, Xinxin Wu, Ying Yang, Qiao Yin, Zhongqiong Jing, Bo Huang, Juan Zhang, Shaqiu Zhang, Lin Liu, Yunya Yu, Yanlin Tian, Bin Pan, Leichang Rehman, Mujeeb Ur Cheng, Anchun Virol J Research BACKGROUND: Tembusu virus (TMUV), a newly emerging pathogenic flavivirus, spreads rapidly between ducks, causing massive economic losses in the Chinese duck industry. Vaccination is the most effective method to prevent TMUV. Therefore, it is urgent to look for an effective vaccine strategy against TMUV. Heterologous prime-boost regimens priming with vaccines and boosting with recombinant adenovirus vaccines have been proven to be successful strategies for protecting against viruses in experimental animal models. METHODS: In this study, heterologous and homologous prime-boost strategies using an attenuated salmonella vaccine and a recombinant adenovirus vaccine expressing prM-E or the E gene of TMUV were evaluated to protect ducks against TMUV infection for the first time, including priming and boosting with the attenuated salmonella vaccine, priming and boosting with the recombinant adenovirus vaccine, and priming with the attenuated salmonella vaccine and boosting with the recombinant adenovirus vaccine. Humoral and cellular immune responses were detected and evaluated. We then challenged the ducks with TMUV at 12 days after boosting to assay for clinical symptoms, mortality, viral loads and histopathological lesions after these different strategies. RESULTS: Compared with the homologous prime-boost strategies, the heterologous prime-boost regimen produced higher levels of neutralizing antibodies and IgG antibodies against TMUV. Additionally, it could induce higher levels of IFN-γ than homologous prime-boost strategies in the later stage. Interestingly, the heterologous prime-boost strategy induced higher levels of IL-4 in the early stage, but the IL-4 levels gradually decreased and were even lower than those induced by the homologous prime-boost strategy in the later stage. Moreover, the heterologous prime-boost strategy could efficiently protect ducks, with low viral titres, no clinical symptoms and histopathological lesions in this experiment after challenge with TMUV, while slight clinical symptoms and histopathological lesions were observed with the homologous prime-boost strategies. CONCLUSIONS: Our results indicated that the heterologous prime-boost strategy induced higher levels of humoral and cellular immune responses and better protection against TMUV infection in ducks than the homologous prime-boost strategies, suggesting that the heterologous prime-boost strategy is an important candidate for the design of a novel vaccine strategy against TMUV. BioMed Central 2020-05-12 /pmc/articles/PMC7218524/ /pubmed/32398028 http://dx.doi.org/10.1186/s12985-020-01334-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pan, Yuting
Jia, Renyong
Li, Juping
Wang, Mingshu
Chen, Shun
Liu, Mafeng
Zhu, Dekang
Zhao, Xinxin
Wu, Ying
Yang, Qiao
Yin, Zhongqiong
Jing, Bo
Huang, Juan
Zhang, Shaqiu
Zhang, Lin
Liu, Yunya
Yu, Yanlin
Tian, Bin
Pan, Leichang
Rehman, Mujeeb Ur
Cheng, Anchun
Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title_full Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title_fullStr Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title_full_unstemmed Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title_short Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
title_sort heterologous prime-boost: an important candidate immunization strategy against tembusu virus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218524/
https://www.ncbi.nlm.nih.gov/pubmed/32398028
http://dx.doi.org/10.1186/s12985-020-01334-w
work_keys_str_mv AT panyuting heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT jiarenyong heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT lijuping heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT wangmingshu heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT chenshun heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT liumafeng heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT zhudekang heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT zhaoxinxin heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT wuying heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT yangqiao heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT yinzhongqiong heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT jingbo heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT huangjuan heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT zhangshaqiu heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT zhanglin heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT liuyunya heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT yuyanlin heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT tianbin heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT panleichang heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT rehmanmujeebur heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus
AT chenganchun heterologousprimeboostanimportantcandidateimmunizationstrategyagainsttembusuvirus